SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer

NCT06666166 | Not Yet Recruiting Phase 2 DMC

• 1 other identifier: GC-IIT-SHR-A1811-Apa
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the effectiveness and safety of SHR-A1811 combined with apatinib in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.

Conditions

Advanced Gastric Carcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Advanced Colorectal Cancer

Keywords

apatinib; advanced gastric or gastroesophageal junction adenocarcinoma; advanced colorectal cancer; SHR-A1811

Outcome Measures

Primary Outcomes (1)

• Objective response rate (ORR)

  To evaluate the efficacy of anti-tumor

  baseline up to approximately 6 month

Secondary Outcomes (5)

• Duration of Response (DOR)

  baseline up to approximately 12 months

• Disease control rate (DCR)

  baseline up to approximately 6 month

• Progression-free survival (PFS)

  baseline up to approximately 6 month

• Overall survival (OS)

  baseline up to approximately 12 month

• Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

  From the initiation of the first dose to 28 days after the last dose

Study Arms (2)

Gastric or gastroesophageal junction adenocarcinoma

EXPERIMENTAL

Drug: SHR-A1811 & Apartinib

Advanced colorectal cancer

EXPERIMENTAL

Drug: SHR-A1811 & Apartinib

Interventions

SHR-A1811 & Apartinib DRUG

SHR-A1811 injection will be administered by intravenous infusion. And apatinib will be administered orally.

Advanced colorectal cancer; Gastric or gastroesophageal junction adenocarcinoma

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants voluntarily enrolled in this study and signed an informed consent form, were compliant and co-operated with follow-up visits;
• Age 18-75 years, including 18 and 75 year, male and female;
• ECOG (Eastern Cooperative Oncology Group) performance status of 0-1;
• Has a life expectancy of greater than 3 months;
• Cohort A: Has histologically confirmed diagnosis of unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma;
• Cohort B: Has histologically confirmed diagnosis of unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma;
• There must be a measurable target lesion that meets the RECIST 1.1 criteria;
• The function of major organs meets the following criteria(not transfused, not using haematopoietic factors and not corrected with drugs within 14 days):
• Absolute neutrophil count (ANC) ≥1.5×10\^9/L;
• PLT ≥100×10\^9/L;
• Hb≥9g/dL;
• ALB≥3.0g/dL;
• total bilirubin ≤1.5 x ULN;
• ALT/AST ≤ 2.5 x ULN (When there is liver metastasis, ALT/AST ≤ 5 x ULN);
• Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr) ≥60mL/min (according to Cockcroft-Gault formula);

You may not qualify if:

• Patients with meningeal metastases; Or patients with brain metastases that have not been treated with surgery or radiation, but those who have been stable for at least one month after treatment and have stopped using steroid drugs (such as 10mg/day prednisone or other equivalent hormones) for more than 2 weeks except;
• Uncontrolled pleural effusion or ascites;
• There are serious concomitant diseases: such as serious cardiovascular and cerebrovascular disease, kidney failure, liver failure, hematopoietic disease, endocrine disease, cachexia, etc;
• Previously received antibody drug conjugate therapy containing topoisomerase I inhibitors, such as trastuzumab deruxtecan (DS-8201), etc; Subjects underwent surgery (except diagnostic surgery), radiotherapy, chemotherapy, macromolecular targeted therapy or immunotherapy within 4 weeks before the first dose of the study drug；Small molecule targeted drugs (including other oral targeted drugs used in clinical trials) whose last dose is less than 5 half-life period or 4 weeks (whichever is shorter) from the first dose; Subjects received palliative radiotherapy or local treatment less than 2 weeks after completion of treatment and before the first dose;
• Subjects who have been treated with live vaccine or attenuated vaccine within 1 month prior to the first dose;
• Subjects requiring systemic therapy with corticosteroids (\>10 mg/day of prednisone or equivalent) or other immunosuppressive agents within 14 days prior to first dose, excluding nasal spray or inhaled corticosteroids.
• The toxicity caused by previous anti-tumor treatments has not recovered to ≤ CTCAE grade 1 (excluding hair loss; according to the researcher's judgment, some tolerable chronic grade II toxicity can be excluded);
• Uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); Active bleeding (such as local active ulcer lesions and fecal occult blood≥ ++), with a history of gastrointestinal bleeding within 6 months;
• Abnormal coagulation function (INR\>1.5 or prothrombin time (PT)\>ULN+4 seconds or APTT\>1.5 × ULN), with a tendency to bleed or undergoing thrombolytic or anticoagulant therapy;
• Subjects were co-administered a potent CYP3A4 or CYP2D6 inhibitor or inducer within 3 weeks prior to first dosing;
• Factors affecting oral administration of medications such as inability to swallow, chronic diarrhoea and intestinal obstruction;
• Any active autoimmune disease or history of autoimmune disease (e.g., autoimmune hepatitis, uveitis, enteritis, pituitary gland inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (may be included after hormone replacement therapy)); and skin disorders (e.g., vitiligo, psoriasis, or alopecia) in which asthma has been in complete remission in childhood and has required no intervention in adulthood or in which systemic therapy is not required.subjects with autoimmune mediated hypothyroidism treated with thyroid replacement hormone at a stable dose and type I diabetes patients treated with insulin at a stable dose can be included;
• Subjects with immunodeficiency disease, such as HIV infection, congenital or acquired immune dysfunction, organ transplantation；
• Uncontrolled heart clinical symptoms or diseases, such as (1) New York Heart Association class II or higher heart failure; (2) unstable angina pectoris; (3) Myocardial ischaemia within 1 year; (4) Subjects with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;
• Complicated severe infection within 30 days prior to first dose, including but not limited to infection complications that require hospitalization, bacteremia, severe pneumonia, etc; active infections that have received therapeutic intravenous antibiotics within 2 weeks prior to the first dose. Subjects receiving prophylactic antibiotic treatment (such as preventing urinary tract infections) can be enrolled;

Sponsors & Collaborators

• Yunpeng Liu: lead
• Jiangsu HengRui Medicine Co., Ltd.: collaborator

Study Sites (1)

The First Hospital of China Medical University

Shenyang, China

Location

Central Study Contacts

Xiujuan Qu

CONTACT

13604031355; cmu1h_zlnk_trial@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: October 29, 2024
• First Posted: October 30, 2024
• Study Start: December 1, 2024
• Primary Completion (Estimated): July 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: October 30, 2024

Record last verified: 2024-10

Locations

CN (1)